

L1 HCAPLUS COPYRIGHT 2003 ACS

Full Text

AN 1990:48816 HCAPLUS

DN 112:48816

TI Vitamin D derivatives for prevention of bone atrophy after fracture or bone surgery

IN Takemitsu, Yoshiharu; Onozawa, Toshihiro; Yoshimura, Shinichiro; Nose, Yoshinori; Yamashita, Izumi; Kamo, Hiroki; Miyatsu, Makoto; Hamada, Osamu; Ariyama, Hiroyuki; et al.

PA Teijin Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 64000021	A2	19890105	JP 1987-110875	19870508 <--
PRAI	JP 1987-43036		19870227		

AB The title vitamin D derivs. are 1 α -hydroxyvitamin D, 1 α ,24-dihydroxyvitamin D, 1 α ,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, 1 α ,24,25-trihydroxyvitamin D, etc. Thus, 1 α -hydroxyvitamin D3 (1 μ g/day) administered to patients with arthritis deformans (from 1 wk prior to surgery to 2 mo postsurgery) effectively presented bone atrophy.

L1 WPIDS (C) 2003 THOMSON DERWENT

Full Text

AN 1989-050483 [07] WPIDS

DNC C1989-022358

TI Osteoporosis preventing drug - contg. active vitamin-D opt. together with calcium and phosphorus cpds., calcitonin, etc..

DC B05

PA (TEIJ) TEIJIN LTD

CYC 1

PI JP 64000021 A 19890105 (198907)* 3p <--

ADT JP. 64000021 A JP 1987-110875 19870508

PRAI JP 1987-43036 19870227; JP 1987-110875 19870508

AN 1989-050483 [07] WPIDS

AB JP 64000021 A UPAB: 19930923

The osteoporosis preventing drug produced after fracture and/or fracture operation, contains active vitamin D as an active component.

Active vitamin D3 is pref. 1 alpha-hydroxy-vitamin D; 1 alpha, 24-dihydroxyvitamin D; 1 alpha, 25-dihydroxyvitamin D; 24,25-dihydroxyvitamin D; 1 alpha,24,25-trihydroxyvitamin D; 24,25-F2-1 alpha, 25-dihydroxyvitamin D; 26,26,26,27,27,27-F6-1a, 25-dihydroxyvitamin D.

USE/ADVANTAGE - By continuous administration of a very little amt. of active vitamin D during or after fracture operation, osteoporosis can be prevented completely, in regardless of patient's ages or osteodensity's difference, similarly. Daily dose of active vitamin D is commonly 0.01-10 micro-g; 1-3 times. The dosage forms are e.g. soft capsules, hard capsules, tablets, syrups, or injections. It can be used jointly with Ca cpds., P cpds., calcitonin, protein anabolic hormone, etc.

0/0

L2 JAPIO COPYRIGHT 2003 JPO

Full Text

AN 1989-000021 JAPIO

TI PREVENTIVE FOR OSTEOPOROSIS

IN TAKEMITSU YOSHIHARU; ONOZAWA TOSHIHIRO; YOSHIMURA SHINICHIRO; NOSE YOSHINORI; YAMASHITA IZUMI; KAMO HIROKI; MIYATSU MAKOTO; HAMADA OSAMU; ARIYAMA HIROYUKI; TOKUHIRO CHO; KAWAGISHI NAOKO; MUGIKURA CHO; MATSUDA YOSHIHARU

PA TEIJIN LTD

PI JP 64000021 A 19890105 Showa

AI JP 1987-110875 (JP62110875 Showa) 19870508

PRAI JP 1987-43036 19870227

SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 1989

AN 1989-000021 JAPIO

AB PURPOSE: To provide the titled preventive containing activated vitamin D as an active component and effective in preventing the systemic osteoporosis occurring after bone fracture and/or operation of bone fracture.

CONSTITUTION: The objective preventive contains an activated vitamin D, e.g. a compound selected from 1-hydroxy-vitamin D, 1-24-, 1,25- or 24,25-dihydroxy- vitamin D, 1,24,25-trihydroxyvitamin D, 24, 25-F<SB>2</SB>-1, 25-dihydroxy-vitamin D and 26,26,26,27,27,27-F<SB>6</SB>-1,25-dihydroxy-vitamin D (especially activated vitamin D<SB>3</SB> of the above type) as an active component. The active component is administered at a rate of usually about 0.0110g/day/person in 13 divided doses per day. Osteoporosis can be completely prevented by continuously administering the agent under the above condition in the operation or during the remedying period of bone fracture independent of the age and the bone density before the operation of the bone fracture.

COPYRIGHT: (C)1989, JPO&Japio